Listed

Petmed Express Inc: Form 10-Q/A for the period ended Sep 30, 2023

Filed with the SEC on Apr 15, 2024 and accepted by EDGAR at Apr 15, 2024, 08:12 ET.

Share

Management's discussion and analysis

As filed, 35,241 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this Amendment, and our 2023 Form 10-K/A.

Certain information in this Amendment includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of 2023 Form 10-K/A under the heading “Risk Factors.” A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of the Original Report as of the date they were made or as otherwise specified herein. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

When used in this Amendment, unless otherwise stated or the context otherwise indicates, "PetMed Express," "PetMeds," "PetMed," "the Company," "we," "our," and "us" refers to PetMed Express, Inc. and its direct and indirect wholly owned subsidiaries, taken as a whole.

Restatement

As described in the Explanatory Note above and in Note 1 to our consolidated financial statements, we have restated our unaudited consolidated financial statements and Item 2. Management’s Discussion of Financial Condition and Results of Operations for the three and six months ended September 30, 2023 and September 30, 2022 in this Amendment.

Executive Summary

PetMed Express, Inc. and subsidiaries, d/b/a PetMeds®, is a leading nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, food, supplements, supplies and vet services for dogs, cats and horses. PetMeds markets and sells directly to consumers through its websites, toll-free numbers, and mobile applications. We offer consumers an attractive option for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service.

Founded in 1996, our executive headquarters offices are located at 420 South Congress Avenue, Delray Beach, Florida 33445, and our telephone number is (561) 526-4444. We have a March 31 fiscal year end.

Presently, our product line includes approximately 15,000 of the most popular pet medications, health products, food and supplies for dogs, cats, and horses. Approximately 9,000 of these items were part of the April 2023 acquisition of PetCareRx.

We market our products through national advertising campaigns and social media which aim to increase the recognition of the “PetMeds®” brand name, increase traffic on our websites at www.petmeds.com (http://www.petmeds.com) and www.petcarerx.com (http://www.petcarerx.com), acquire new customers, and maximize repeat purchases. Our sales consist of products sold mainly to retail consumers. The average purchase was approximately $94 for the quarter ended September 30, 2023, approximately $93 for the quarter ended September 30, 2022, approximately $95 for the six months ended September 30, 2023 and approximately $94 for the six months ended September 30, 2022.

Critical Accounting Policies

Our discussion and analysis of our financial condition and the results of our operations contained herein are based upon our condensed consolidated financial statements and the data used to prepare them. Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, and income taxes. We base our estimates and judgments on our historical experience, knowledge of current conditions, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies.

Revenue recognition

We account for revenue under Accounting Standards Codification ("ASC") Topic 606 ("Revenue from Contracts with Customers") and generate revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on our website are drop shipped to customers. We consider ourselves the principal in the arrangement because we control the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however this is not considered a key judgment. There are no amounts excluded from the variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time where we have a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership.

Outbound shipping and handling fees are an accounting policy election and are included in sales as we consider ourself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales. Virtually all of our sales are paid by credit cards and we usually receive the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales.

Membership fees represent the amounts recognized periodically from the PetPlus memberships provided through PetCareRx. In addition to annual membership fees earned under the PetPlus program, we also earns membership fees on a month-to-month basis as earned under our monthly partner program. Memberships provide wholesale pricing, free standard shipping, veterinary telehealth services and local Caremark Pharmacy prescription pickup. The PetPlus membership fee is an annual charge and automatically renews one year from the initial enrollment date. We recognize the revenue ratably over the term of the membership which is generally one year.

We maintain an allowance for doubtful accounts for losses that we estimate will arise from customers’ inability to make required payments, arising from either credit card chargebacks or insufficient funds checks. We determine our estimates of the uncollectibility of accounts receivable by analyzing historical and current bad debts and economic trends in compliance with the provisions of ASC Topic 326 ("Financial Instruments - Credit Losses"). The allowance for doubtful accounts was approximately $44 thousand at September 30, 2023, compared to $35 thousand at March 31, 2023.

Business Combinations

We account for our business combinations using the acquisition method of accounting in accordance with ASC Topic 805 ("Business Combinations"). The purchase price is allocated to the fair value of the assets acquired and liabilities assumed. Transaction costs directly attributable to the acquisition are expensed as incurred. Identifiable assets and liabilities acquired or assumed are measured separately at their fair values as of the acquisition date. The excess of the purchase price of acquisition over the fair value of the identifiable net assets of the acquiree is recorded as goodwill. The results of businesses acquired in a business combination are included in our unaudited condensed consolidated financial statements from the date of acquisition.

Determining the fair value of assets acquired and liabilities assumed requires management to use significant judgment and estimates, including the selection of valuation methodologies, estimates of future revenue and cash flows, discount rates and selection of comparable companies. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions, and competition. In connection with the determination of fair values, we may engage a third-party valuation specialist to assist with the valuation of intangible and certain tangible assets acquired and certain obligations assumed. Acquisition-related transaction costs incurred by us are not included as a component of consideration transferred but are accounted for as an operating expense in the period in which the costs are incurred.

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the attached unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Acquisition

On April 3, 2023, we acquired 100% of the issued and outstanding equity interests of PetCareRx, Inc. (“PetCareRx”), a New York corporation and a leading supplier of pet food, pet medications, and supplies. The acquisition was completed pursuant to an Agreement and Plan of Merger ("Merger Agreement") by and among us, Harry Merger Sub, Inc., a New York corporation and a wholly-owned subsidiary of the Company ("Merger Sub"), PetCareRx and Jeanette Loeb (as representative of the PetCareRx equity holders). The Merger Agreement provided for our acquisition of PetCareRx pursuant to the merger of Merger Sub with and into PetCareRx, with PetCareRx as the surviving corporation. The aggregate purchase price consideration was $36.1 million and was funded from our cash on hand.

The fair values of intangible assets acquired consist of a trade name, customer relationships, and developed technology, which were estimated by applying various discounted cash flow models such as the relief from royalty rate for the trade name, the multi-period excess earnings method for the customer relationships, and the cost to replace method for the developed technology. The fair value measurements were based on significant inputs that are not observable (Level 3). The assumptions made by management in determining the fair value of intangible assets included a discount rate of 12% based on the weighted average cost of capital.

Income taxes (As Restated)

We account for income taxes under the provisions of ASC Topic 740 (“Accounting for Income Taxes”), which generally requires recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in our condensed consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse.

As a result of the acquisition, we performed an Internal Revenue Code Section 382 analysis to determine if the net operating losses carried forward will have a utilization limitation. Any limitation may result in the expiration of a portion of the federal net operating loss carryforward before utilization, which would reduce our gross deferred tax assets. As of April 3, 2023, and prior to the acquisition, PetCareRx had approximately $96.0 million of net operating losses and $1.9 million of disallowed interest expense. The restated results of the Section 382 analysis determined the net operating loss and disallowed interest expense in total, would be limited and reduced to $14.5 million.

Economic Conditions, Challenges, and Risks

Macroeconomic factors, including inflation, increased interest rates, significant capital market and supply chain volatility, and global economic and geopolitical developments, have direct and indirect impacts on our results of operations that are difficult to isolate and quantify. In addition, rising fuel, utility, and food costs, rising interest rates, and recessionary fears may impact customer demand and our ability to forecast consumer spending patterns. We also expect the current macroeconomic environment and enterprise customer cost optimization efforts to impact our revenue growth rates. We expect some or all of these factors to continue to impact our operations for the remainder of fiscal 2024.

Results of Operations (As Restated)

The following should be read in conjunction with our unaudited Condensed Consolidated Financial Statements and the related notes thereto included elsewhere herein. The following table sets forth, as a percentage of sales, certain operating data appearing in our unaudited Condensed Consolidated Statements of (Loss) Income:

Three Months Ended September 30, 2023 (as restated) 2022 Six Months Ended September 30, 2023 (as restated) 2022
Sales 100.0% 100.0% 100.0% 100.0%
Cost of sales 71.7 71.9 71.5 71.8
Gross profit 28.3 28.1 28.5 28.2
Operating expenses:
General and administrative 16.8 15.1 18.5 14.2
Advertising 7.8 5.9 8.6 7.6
Depreciation and amortization 2.4 1.3 2.3 1.2
Total operating expenses 27.0 22.4 29.4 23.0
(Loss) income from operations 1.3 5.7 (0.9) 5.2
Total other income 0.6 0.4 0.7 0.1
Income (loss) before provision for income taxes 1.9 6.1 (0.2) 5.3
Provision for income taxes 0.8 1.7 0.2 1.2
Net (loss) income 1.1% 4.4% (0.4)% 4.1%

Non-GAAP Financial Measures

Adjusted EBITDA

To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense, depreciation and amortization, income tax provision, interest income (expense), and other non-operational expenses. We have provided reconciliations below of net income to adjusted EBITDA, the most directly comparable GAAP financial measures.

We have included adjusted EBITDA herein because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.

We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other non-operational expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
  • Adjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
  • Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
  • Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
  • Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
  • Adjusted EBITDA does not reflect certain non operating expenses (income) including sales tax expense (income) relating to recording a liability for sales tax we did not collect from our customers.
  • Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.

Because of these and other limitations, adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.

The following tables present a reconciliation of net income, the most directly comparable GAAP measure, to adjusted EBITDA for each of the periods indicated:

($ in thousands, except percentages)

Consolidated Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA:

Three Months Ended September 30, 2023 (as restated) September 30, 2022 (as restated) Increase (Decrease) $%
Net Income $715 $2,881 $(2,166) (75)%
Add (subtract):
Share-based Compensation 1,728 1,681 47 3%
Income Taxes 565 1,087 (522) (48)%
Depreciation and Amortization 1,713 858 855 100%
Interest (Income) Expense, Net (1) (151) 14 (165) n/m
Acquisition/Partnership Transactions and Other Items 168 – 168 n/m
Employee Severance 15 364 (349) (96)%
Sales Tax Expense (Income) (1,316) 165 (1,481) n/m
Adjusted EBITDA $3,437 $7,050 $(3,613) (51)%

(1) Included in interest (income) expense is $419 thousand of interest expense related to the sales tax liability and $570 thousand of interest income for the three months ended September 30, 2023 and $402 thousand of interest expense related to the sales tax liability and $388 thousand of interest income for the three months ended September 30, 2022.

($ in thousands, except percentages)

Consolidated Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA:

Six Months Ended September 30, 2023 (as restated) September 30, 2022 (as restated) Increase (Decrease) $%
Net (Loss) Income $(421) $5,568 $(5,989) (108)%
Add (subtract):
Share-based Compensation 3,488 3,217 271 8%
Income Taxes 273 1,635 (1,362) (83)%
Depreciation and Amortization 3,391 1,611 1,780 110%
Interest (Income) Expense, Net (1) (345) 288 (633) (220)%
Acquisition/Partnership Transactions and Other Items 1,294 355 939 265%
Employee Severance 408 364 44 12%
Sales Tax Expense (Income) (1,316) 344 (1,660) n/m
Adjusted EBITDA $6,772 $13,382 $(6,610) (49)%

(1) Included in interest (income) expense is $845 thousand of interest expense related to the sales tax liability and $1,190 thousand of interest income for the six months ended September 30, 2023 and $793 thousand of interest expense related to the sales tax liability and $505 thousand of interest income for the six months ended September 30, 2022.

Three Months Ended September 30, 2023 Compared With Three Months Ended September 30, 2022 and Six Months Ended September 30, 2023 Compared With Six Months Ended September 30, 2022

Sales (As Restated)

Sales increased by approximately $5.7 million, or 8.8%, to approximately $71.0 million for the quarter ended September 30, 2023, compared to approximately $65.3 million for the quarter ended September 30, 2022. Sales increased by approximately $13.9 million, or 10.3%, to approximately $149.2 million for the six months ended September 30, 2023, compared to approximately $135.3 million for the six months ended September 30, 2022. The increase in sales for the three and six months ended September 30, 2023 was due to incremental sales and membership fees from the integration of PetCareRx and growth in PetMeds new customer sales, partially offset by declines in PetMeds reorder sales.

We acquired approximately 76,000 new customers for the quarter ended September 30, 2023 compared to approximately 61,000 new customers for the quarter ended September 30, 2022. We acquired approximately 162,000 new customers for the six months ended September 30, 2023 compared to approximately 130,000 new customers for the six months ended September 30, 2022. The following tables illustrates sales by various sales classifications:

Three Months Ended September 30, Increase (Decrease)
Revenue (In thousands) 2023% 2022% $%
(as restated)
Reorder sales $62,403 87.9% $59,607 91.3% $2,796 4.7%
New order sales 6,172 8.7% 5,653 8.7% 519 9.2%
Membership fees 2,424 3.4% – –% 2,424 –%
Total net sales $70,999 100.0% $65,260 100.0% $5,739 8.8%
Six Months Ended September 30, Increase (Decrease)
Revenue (In thousands) 2023% 2022% $%
(as restated)
Reorder sales $130,441 87.4% $122,815 90.8% $7,626 6.2%
New order sales 13,992 9.4% 12,487 9.2% 1,505 12.1%
Membership fees 4,810 3.2% – –% 4,810 –%
Total net sales $149,243 100.0% $135,302 100.0% $13,941 10.3%

We remain encouraged by the adoption of our AutoShip program and have seen an increasingly positive trend over the last several quarters since we launched this program. For example, our quarterly AutoShip percentage was 51.0% of net sales for the most recent quarter ended September 30, 2023, up from 38.9% of net sales for the same period last year and up from 48.7% of net sales sequentially in the prior quarter.

Going forward, sales may be adversely affected due to increased competition and consumers giving more consideration to price. The changes in consumer behavior due to macroeconomic factors makes future sales somewhat challenging to predict. No guarantees can be made that sales will grow in the future.

Cost of sales (As Restated)

Cost of sales increased by approximately $4.0 million, or 8.5%, to approximately $50.9 million for the quarter ended September 30, 2023, from approximately $46.9 million for the quarter ended September 30, 2022. Cost of sales increased by approximately $9.5 million, or 9.7%, to approximately $106.7 million, from approximately $97.2 million for the six months ended September 30, 2022. Cost of sales, as a percentage of sales, was essentially flat for the quarter and six months ended September 30, 2023. The cost of sales increases for the quarter and six months ended September 30, 2023 compared to the quarter and six months ended September 30, 2022 was primarily due to higher sales over the same period.

Gross profit (As Restated)

Gross profit increased by approximately $1.7 million, or 9.5%, to approximately $20.1 million for the quarter ended September 30, 2023, from approximately $18.3 million for the quarter ended September 30, 2022. For the six months ended September 30, 2023, gross profit increased by approximately $4.5 million, or 11.7%, to approximately $42.6 million, from approximately $38.1 million for the six months ended September 30, 2022. The gross profit increases for the quarter and six months ended September 30, 2023 compared to the quarter and six months ended September 30, 2022 was primarily due to higher sales and higher profit margins obtained by PetCareRx driven by membership fees.

General and administrative expenses (As Restated)

General and administrative expenses increased by approximately $2.1 million, or 21.3%, to approximately $12.0 million for the quarter ended September 30, 2023, from approximately $9.9 million for the quarter ended September 30, 2022. The increase to general and administrative expenses for the quarter ended September 30, 2023 was due to a $1.4 million increase in payroll expenses, a $0.5 million increase of professional fees, of which $0.2 million were acquisition related costs and a $0.7 million increase of software and systems expense, and a $1.1 million increase of variable and other overhead expenses. The expense increases were partially attributed to the integration of PetCareRx. These increases were offset by $1.3 million related to sales tax settlements with states.

For the six months ended September 30, 2023 general and administrative expenses increased by approximately $8.4 million, or 43.8%, to approximately $27.7 million, from approximately $19.2 million for the six months ended September 30, 2022. The increase to general and administrative expenses for the six months ended September 30, 2023 was due to a $4.7 million increase in payroll expenses, of which $0.3 million is from increased stock compensation, a $2.1 million increase of professional fees, of which $0.9 million were acquisition related costs, a $1.3 million increase of software and systems expense, and a $1.9 million increase of variable and other overhead expenses. The expense increases were partially attributed to the combination of PetCareRx. These increases were offset by $1.3 million related to sales tax settlements with states.

Advertising Expenses

Advertising expenses increased by approximately $1.6 million, or 42.1%, to approximately $5.5 million for the quarter ended September 30, 2023, from approximately $3.9 million for the quarter ended September 30, 2022. The increase for the quarter can be mainly attributed to media spend related to PetCareRx. The advertising costs of acquiring a new customer, defined as total advertising costs divided by new customers acquired, was $73 for the quarter ended September 30, 2023 compared to $64 for the quarter ended September 30, 2022. The increase to customer acquisition costs for the quarter ended September 30, 2023, was due to a less efficient variable marketing spend. The advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, spending, and price competition. Historically, the advertising environment fluctuates due to supply and demand. A more favorable advertising environment may positively impact future sales, whereas a less favorable advertising environment may negatively impact future sales. As a percentage of sales, advertising expense was 7.8% and 5.9% for the quarters ended September 30, 2023 and 2022, respectively. The advertising percentage may fluctuate quarter to quarter due to seasonality and advertising availability.

For the six months ended September 30, 2023 advertising expenses increased by approximately $2.5 million, or 24.9%, to approximately $12.8 million, from approximately $10.2 million for the six months ended September 30, 2022. The increase was due to media spend related to PetCareRx compared to the same period in the prior year. The advertising costs of acquiring a new customer was flat at $79 and $79 for the six months ended September 30, 2023 and 2022, respectively. As a percentage of sales, advertising expense was 8.6% and 7.6% for the six months ended September 30, 2023 and 2022, respectively.

Depreciation and amortization

Depreciation and amortization expense was $1.7 million and $0.9 million for the quarters ended September 30, 2023 and September 30, 2022, respectively. Depreciation and amortization expense was $3.4 million and $1.6 million for the six months ended September 30, 2023 and 2022, respectively. This increase to depreciation and amortization expense for the quarter and the six months ended September 30, 2023 can be attributed to new property and equipment additions, as well as the intangibles acquired from PetCareRx .

Other income (As Restated)

Other income increased to approximately $0.4 million for the quarter ended September 30, 2023 compared to approximately $0.2 million for the quarter ended September 30, 2022. Other income increased to approximately $1.1 million for the six months ended September 30, 2023 compared to approximately $0.2 million for the six months ended September 30, 2022. The increase to other income for the quarter was due to higher interest rates which more than offset slightly lower invested balances. The increase to other income for the six months was primarily related to additional interest income as a result of higher interest rates, as well as increased rental income from PetCareRx. Interest income may decrease in the future based on several factors, including utilization of our cash balances on future investments or partnerships, on our operating activities, towards quarterly dividend payments, or on our share repurchase plan, which has approximately $28.7 million remaining as of September 30, 2023. Additionally, interest income could increase or decrease if the current interest rate environment changes.

Provision for income taxes (As Restated)

For the quarters ended September 30, 2023 and 2022, the Company recorded an income tax provision of approximately $0.6 million and a tax provision of approximately $1.1 million, respectively, and for the six months ended September 30, 2023 and 2022, the Company recorded an income tax provision of approximately $0.3 million and a tax provision of approximately $1.6 million, respectively. The decrease in the tax provision for the three and six months ended September 30, 2023 is related to the decrease in operating income. The effective tax rate for the quarter ended September 30, 2023 was approximately 44.1%, compared to approximately 27.4% for the quarter ended September 30, 2022, and the effective tax rate for the six months ended September 30, 2023 was approximately (184.5)% compared to approximately 22.7% for the six months ended September 30, 2022. The increase to the effective tax rate for the three months ended September 30, 2023 can be attributed to net operating losses offsetting taxable income partially offset by an increase in state income tax. The decrease to the effective tax rate for the six months ended September 30, 2023 can be attributed to non-deductible items and an increase in state income tax.

Liquidity and Capital Resources

Our working capital at September 30, 2023 and March 31, 2023 was $23.4 million and $72.9 million, respectively. The $49.5 million decrease in working capital was primarily attributable to a decrease in cash used to fund the $36.1 million PetCareRx acquisition, and a $3.2 million increase in inventory in part related to the acquisition of PetCareRx. Net cash used in operating activities was $0.2 million for the six months ended September 30, 2023, compared to cash provided by operating activities of $5.1 million for the six months ended September 30, 2022. This change is primarily due to decreases in net income and accounts payable and an increase in inventory in the six months ended September 30, 2023 compared to the same period in the prior year. Net cash used in investing activities was $38.0 million for the six months ended September 30, 2023, compared to $7.3 million used in investing activities for the six months ended September 30, 2022. The change in net cash used in investing activities is related to the PetCareRx acquisition, and increased property and equipment acquired during the six months ended September 30, 2023. Net cash used in financing activities was $12.4 million and $12.3 million for the six months ended September 30, 2023 and the six months ended September 30, 2022, respectively, due to the payment of an aggregate $0.60 per share dividend .

As of September 30, 2023, we had approximately $28.7 million remaining under our share repurchase plan. On October 30, 2023, our Board of Directors elected to suspend the quarterly dividend. This move is intended to focus use of the Company’s existing cash flow on growth initiatives and other, higher return initiatives. The declaration and payment of future dividends is discretionary and will be subject to the determination by the Board of Directors.

As of September 30, 2023, we had $1.8 million in outstanding lease commitments assumed for the leases on two buildings occupied by PetCareRx. Other than the foregoing leases, we are not currently bound by any material long-term or short-term commitments for the purchase or lease of capital expenditures. Any material amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately provide for any future increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future. Our primary source of working capital is cash from operations. We presently have no alternative sources of working capital and have no commitments.

Market risk

As filed, 1,626 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Market risk generally represents the risk that losses may occur in the value of financial instruments as a result of movements in interest rates, foreign currency exchange rates, and commodity prices. Our financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The book values of cash equivalents, accounts receivable, and accounts payable are considered to be representative of fair value because of the short maturity of these instruments. Interest rates affect our return on excess cash and cash equivalents. At September 30, 2023, we had $53.5 million in cash and cash equivalents, and the majority of our cash and cash equivalents generate interest income based on prevailing interest rates. A significant change in interest rates would impact the amount of interest income generated from our excess cash and cash equivalents. It would also impact the market value of our cash and cash equivalents. Our cash and cash equivalents are subject to market risk, primarily interest rate and credit risk. Our cash and cash equivalents are managed by a limited number of outside professional managers within investment guidelines set by our Board of Directors. Such guidelines include security type, credit quality, and maturity, and are intended to limit market risk by maintaining cash in federally-insured bank deposit accounts and restricting cash equivalents to highly-liquid investments with maturities of three months or less. We do not hold any derivative financial instruments that could expose us to significant market risk. At September 30, 2023, we had no debt obligations.

Controls and procedures

As filed, 6,223 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a‑15(e) and 15d-15(e) promulgated under the Exchange Act). Based on such evaluation, at the time the Original Report was filed, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2023 to provide reasonable assurance that information to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and (ii) accumulated and communicated to management, including our principal executive and principal financial officers or persons performing similar functions, as appropriate to allow timely decisions regarding disclosure. Subsequent to the original evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2023, due to the material weaknesses described below.

Material Weakness

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Per the 2023 Form 10-K/A we identified a material weakness due to a lack of segregation of duties over the preparation, approval and posting of certain journal entries. Subsequent to our original evaluation, we identified a new material weakness in the design of our controls relating to the review of the appropriate application of GAAP relating to our sales tax liability in our consolidated financial statements. This material weakness resulted in the restatement of our financial statements as of and for the years ended March 31, 2023, 2022 and 2021, the unaudited condensed consolidated quarterly financial information for the quarterly periods in the fiscal years ended March 31, 2023 and 2022, and the unaudited condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2023 and September 30, 2023. Subsequent to our original evaluation, we also identified a material weakness in the design of our controls over accurate valuation of our deferred tax asset and goodwill relating to our acquisition of PetCareRx in April 2023. This material weakness resulted in the restatement of our unaudited condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2023 and September 30, 2023.

These material weaknesses remain unremediated as of September 30, 2023. Management is taking steps to remediate these material weaknesses (see “Remediation of Material Weaknesses” for details).

Remediation of Material Weaknesses

We are committed to maintaining a strong internal control environment and implementing measures designed to help ensure that control deficiencies contributing to the material weaknesses are remediated as soon as possible. We are developing a remediation plan designed to improve our internal controls over financial reporting to remediate these material weaknesses, including increasing resources and modifying processes to eliminate the lack of segregation of duties over the preparation, approval and posting of journal entries and engaging consultants to assist with complex areas of U.S. GAAP and SEC rules to facilitate accurate and timely financial reporting.

Additionally, in response to the material weakness due to the tax calculations, we have developed and are in the process of implementing a remediation plan. The key elements of the plan include:

1. Enhancing the oversight and review of tax-related accounting estimates and calculations to ensure they are complete and accurate.

2. Providing additional training to personnel involved in tax accounting and financial reporting to enhance their understanding of the relevant accounting standards and requirements.

3. Enhancing the documentation of tax positions and related accounting judgments to ensure they are adequately supported and can withstand external scrutiny.

The material weaknesses will not be remediated until our remediation plan has been fully developed and implemented, the applicable controls operate for a sufficient period of time, and we have concluded, through testing, that the newly implemented and enhanced controls are operating effectively. We are continuing to work on the implementation of our remediation plan, following which we will continue to test and monitor the new and enhanced controls until management has concluded that they are designed and operating effectively. We may conclude that additional measures, including resources, are necessary to remediate the material weaknesses in our internal control over financial reporting, which may necessitate additional evaluation and implementation time. We may also modify certain of the remediation efforts described above.

Changes in Internal Control Over Financial Reporting

Other than as described above, there were no changes in our internal control over financial reporting during our fiscal quarter ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design and disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgement in evaluating the benefits of possible controls and procedures relative to the their cost.

Risk factors

As filed, 446 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, results of operations, and trading price of our common stock. Please refer to our 2023 Form 10-K/A for additional information concerning these and other uncertainties that could negatively impact the Company. There have been no material changes to the risk factors disclosed in our 2023 Form 10-K/A.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue3 months2023-07-01 to 2023-09-30$50.9mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2023-04-01 to 2023-09-30$106.7mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2023-07-01 to 2023-09-30$20.1mus-gaap:GrossProfit
Gross profit6 months2023-04-01 to 2023-09-30$42.6mus-gaap:GrossProfit
Operating income3 months2023-07-01 to 2023-09-30$875.0kus-gaap:OperatingIncomeLoss
Operating income6 months2023-04-01 to 2023-09-30−$1.3mus-gaap:OperatingIncomeLoss
Income tax3 months2023-07-01 to 2023-09-30$565.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2023-04-01 to 2023-09-30$273.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2023-07-01 to 2023-09-30$715.0kus-gaap:NetIncomeLoss
Net income6 months2023-04-01 to 2023-09-30−$421.0kus-gaap:NetIncomeLoss
Diluted EPS3 months2023-07-01 to 2023-09-30$0.03us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2023-04-01 to 2023-09-30−$0.02us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-07-01 to 2023-09-30$0.04us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-04-01 to 2023-09-30−$0.02us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-07-01 to 2023-09-3020,780,455 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2023-04-01 to 2023-09-3020,357,752 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2023-04-01 to 2023-09-30−$215.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2023-04-01 to 2023-09-30$2.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid6 months2023-04-01 to 2023-09-30$12.4mus-gaap:PaymentsOfDividendsCommonStock
Cash and equivalentsAt period end2023-09-30$53.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-09-30$84.6mus-gaap:AssetsCurrent
Total assetsAt period end2023-09-30$162.7mus-gaap:Assets
Current liabilitiesAt period end2023-09-30$61.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-09-30$62.3mus-gaap:Liabilities
Shareholders' equityAt period end2023-09-30$100.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001040130-24-000018. Last ingested by Listed: Nov 13, 2026, 14:26 ET. Listed shows no prices and gives no investment advice.